A novel antibody has shown promise for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, researchers say.
The Ab-IPL-IL-17™ antibody targets a specific section of both interleukin-17A and F, which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.